← FDA DRUG APPROVALS

FDA ANDA · ANDA204475

FENOFIBRATE

Sponsor: MYLAN PHARMS INC

APPLICATION
ANDA204475
TYPE
ANDA
ORIGINAL APPROVAL
2016-06-23
LATEST ACTION
2022-01-04
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

FENOFIBRATEPrescription
FENOFIBRATE 40MG · TABLET · ORAL
FENOFIBRATEPrescription
FENOFIBRATE 120MG · TABLET · ORAL

Approval history

2022-01-04Labeling · Supplement 5 · standardAP
2022-01-04Labeling · Supplement 3 · standardAP
2022-01-04Labeling · Supplement 2 · standardAP
2016-06-23UNKNOWN · OriginalLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →